Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 9:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 1,573 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Biological Control Clear all
Completed Phase 2 Interventional

Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer

NCT00004132
View directory record Official record
Conditions
Drug/Agent Toxicity by Tissue/Organ, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Oral Complications, Radiation Toxicity
Interventions
filgrastim, palifermin, cyclophosphamide, etoposide, ifosfamide, quality-of-life assessment, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
12 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 26, 2013 · Synced Oct 25, 2026, 9:50 PM EDT
Completed Phase 2 Interventional Results available

Live Zoster Vaccine in HIV-Infected Adults on Antiretroviral Therapy

NCT00851786
View directory record Official record
Conditions
Herpes Zoster, HIV Infections
Interventions
ZOSTAVAX, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
43
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 30 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 25, 2026, 9:50 PM EDT
Completed Not applicable Interventional

A Study Evaluating the Hair Regrowth Efficacy and Safety of ALRV5XR in Female Subjects With Hair Loss

NCT04450602
View directory record Official record
Conditions
Androgenetic Alopecia, Androgenic Alopecia, Telogen Effluvium, Thinning Hair, Hair Loss/Baldness, Hair Thinning
Interventions
ALRV5XR, ALRV5XR Shampoo, ALRV5XR Conditioner, ALRV5XR Hair Follicle Serum (Nutriment), Placebo, Placebo Shampoo, Placebo Conditioner, Placebo Hair Follicle Serum (Nutriment)
Dietary Supplement · Other
Lead sponsor
Arbor Life Labs
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 30, 2020 · Synced Oct 25, 2026, 9:50 PM EDT
Completed Phase 3 Interventional Results available

Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment

NCT02873936
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Filgotinib, Placebo to match filgotinib, csDMARDs
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
449 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
55
States / cities
Huntsville, Alabama • Gilbert, Arizona • Covina, California + 52 more
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Oct 25, 2026, 9:50 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV-002

NCT02334436
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
Botulinum toxin, Type A, 0.9% sterile, unpreserved saline
Biological · Other
Lead sponsor
Evolus, Inc.
Industry
Eligibility
18 Years and older
Enrollment
324 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Mar 27, 2019 · Synced Oct 25, 2026, 9:50 PM EDT
Recruiting Phase 1 Interventional

A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults

NCT07464314
View directory record Official record
Conditions
Influenza, Human+COVID-19
Interventions
Investigational mRNA Seasonal Flu/COVID-19 Combination (Flu/COVm) Vaccine, Licensed Seasonal Influenza Vaccine, Licensed COVID-19 Vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
65 Years to 85 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
12
States / cities
Anniston, Alabama • Little Rock, Arkansas • Fair Oaks, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 25, 2026, 9:50 PM EDT
Recruiting Phase 4 Interventional

Safety of the Herpes Zoster Subunit Vaccine in Lupus

NCT05559671
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Herpes Zoster Subunit (HZ/su) Vaccine, Placebo
Biological
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 90 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
New York, New York • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Dec 26, 2025 · Synced Oct 25, 2026, 9:50 PM EDT
Active, not recruiting Phase 4 Interventional

Angiotensin 2 for AKI After OLT

NCT04592744
View directory record Official record
Conditions
Cirrhosis, Liver, End Stage Liver DIsease, Acute Kidney Injury, Liver Transplant; Complications
Interventions
Angiotensin II, Norepinephrine
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 25, 2026, 9:50 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Detecting Autologous Transfusion by Measuring Alterations in the Dynamics of Red Blood Cell Maturation and Recycling

NCT02684747
View directory record Official record
Conditions
Blood Transfusion, Autologous, Blood Doping
Interventions
Autologous Transfusion, Control - Normal Saline (Placebo)
Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 35 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 14, 2018 · Synced Oct 25, 2026, 9:50 PM EDT
Terminated Phase 3 Interventional Results available

Calcium and Magnesium in Preventing Peripheral Neuropathy Caused by Ixabepilone in Patients With Breast Cancer

NCT00998738
View directory record Official record
Conditions
Neuropathy, Pain, Recurrent Breast Carcinoma, Stage IV Breast Cancer
Interventions
Calcium Gluconate, Magnesium Sulfate, Placebo, Quality-of-Life Assessment, Questionnaire Administration, Ixabepilone
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 4, 2016 · Synced Oct 25, 2026, 9:50 PM EDT
Completed Phase 4 Interventional Results available

Cryoanalgesia vs. Epidural in the Nuss Procedure

NCT02721017
View directory record Official record
Conditions
Pectus Excavatum, Funnel Chest
Interventions
Cryoanalgesia, Thoracic epidural (ropivicaine, fentanyl)
Device · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
13 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 5, 2021 · Synced Oct 25, 2026, 9:50 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Calcium Supplementation for a Healthy Weight (CaSHeW)

NCT01363115
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Orange Juice fortified with Calcium and Vitamin D, Orange juice without Ca or VitD, Nutritional Counseling
Dietary Supplement · Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 1, 2011 · Synced Oct 25, 2026, 9:50 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Novel Multimodal Pain Control Protocol for Minimally Invasive Gynecologic Surgery

NCT04710277
View directory record Official record
Conditions
Postoperative Pain, Narcotic Use, Cryotherapy Effect
Interventions
Opioid-sparing multimodal pain management, Usual care
Other
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older · Female only
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 12, 2023 · Synced Oct 25, 2026, 9:50 PM EDT
Terminated Phase 2 Interventional

InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection ( ILIAD-7-US-I )

NCT04442178
View directory record Official record
Conditions
COVID-19, Lymphocytopenia
Interventions
CYT107, Placebo
Drug
Lead sponsor
Revimmune
Industry
Eligibility
25 Years to 80 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
Gainesville, Florida • St Louis, Missouri • New Brunswick, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2022 · Synced Oct 25, 2026, 9:50 PM EDT
Completed Phase 2 Interventional Results available

Nilotinib in Parkinson's Disease

NCT03205488
View directory record Official record
Conditions
Parkinson Disease
Interventions
Cohort 1:Nilotinib Oral Capsules (150mg or 300mg), Cohort 2: Nilotinib Oral Capsules (dose to be determined from Cohort 1), Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
40 Years to 79 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
24
States / cities
Birmingham, Alabama • Sun City, Arizona • Sacramento, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2020 · Synced Oct 25, 2026, 9:50 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of a Booster Dose of Meningococcal Diphtheria Toxoid Conjugate Vaccine in Adolescents

NCT00777790
View directory record Official record
Conditions
Meningitis, Meningococcemia
Interventions
Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
13 Years to 21 Years
Enrollment
241 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
9
States / cities
Atlanta, Georgia • Marietta, Georgia • Woburn, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2014 · Synced Oct 25, 2026, 9:50 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of DYSPORT® Using 2mL Dilution in Adults With Cervical Dystonia.

NCT01753310
View directory record Official record
Conditions
Cervical Dystonia
Interventions
Botulinum toxin type A, Placebo
Biological · Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
42
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2019 · Synced Oct 25, 2026, 9:50 PM EDT
Completed Phase 3 Interventional Results available

A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti -Tumor Necrosis Factor (TNF) Alpha Agent(s)

NCT03162796
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
Guselkumab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
383 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
9
States / cities
Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Oct 25, 2026, 9:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Safety and Immune Response Study to Evaluate Varying Doses of an mRNA Vaccine Against Coronavirus Disease 2019 (COVID-19) in Healthy Adults

NCT05972993
View directory record Official record
Conditions
COVID-19
Interventions
mRNA-CR-04 vaccine 10μg, mRNA-CR-04 vaccine 30μg, mRNA-CR-04 vaccine 100μg, Placebo, mRNA-CR-04 vaccine 3μg
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 49 Years
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
4
States / cities
San Diego, California • Melbourne, Florida • Peoria, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Oct 25, 2026, 9:50 PM EDT
Completed Not applicable Interventional Results available

Biologic Mechanisms of Early Exercise After Intracerebral Hemorrhage

NCT04027049
View directory record Official record
Conditions
Intracerebral Hemorrhage, Acute Ischemic Stroke
Interventions
Supine cycle ergometry of the lower extremities
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 1, 2024 · Synced Oct 25, 2026, 9:50 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

DRIIVE (Data and Research on Interventions to Improve the Vehicular Environment)

NCT02381626
View directory record Official record
Conditions
Vehicular Environment
Interventions
HEPA air purifier, questionnaires, Log-book, Urine sample
Device · Behavioral · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years to 90 Years · Male only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 5, 2021 · Synced Oct 25, 2026, 9:50 PM EDT
Completed Phase 3 Interventional Results available

rVWF IN PROPHYLAXIS

NCT02973087
View directory record Official record
Conditions
Von Willebrand Disease
Interventions
von Willebrand factor (Recombinant), Antihemophilic Factor (Recombinant)
Biological
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
8
States / cities
Loveland, Colorado • Gainesville, Florida • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2021 · Synced Oct 25, 2026, 9:50 PM EDT
Completed Phase 2 Interventional

A Study of the Safety and Clinical Effects of Interferon Gamma-1b in Patients With Idiopathic Pulmonary Fibrosis (IPF)

NCT00047658
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Interferon-gamma 1b
Drug
Lead sponsor
InterMune
Industry
Eligibility
20 Years to 79 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 6, 2007 · Synced Oct 25, 2026, 9:50 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Responses to Influenza Vaccine in Patients With Mitochondrial Disorders (MELAS)

NCT01831934
View directory record Official record
Conditions
MELAS Syndrome
Interventions
Fluzone®
Biological
Lead sponsor
Stanford University
Other
Eligibility
13 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 25, 2026, 9:50 PM EDT